Convoy Therapeutics

Description

• BETTER SOLUTIONS, BETTER HEALTHConvoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoys platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoys platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth.
• 

  Headquarters:405 West Cool Dr Suite 107, Oro Valley, Arizona, United States

  More
• 

  Phone Number: +1 520-300-8520

• 

  Website: https://www.convoytx.com

• 

  Employees:0

• 

  Revenue:$0 - 1M

• 

  Legal Name:Convoy Therapeutics

• Convoy Therapeutics's Social Media

  
• Is this data correct?

• |  NAICS Code: 325414  |

  Show More